1341 PharmaBio Delegate Booklet

1341 PharmaBio Delegate Booklet 28/11/07 14:41 Page 10
Speakers
Mr Reynold W (Pete) Mooney
Global Leader, Life Sciences Consulting
Deloitte Consulting LLP
Mr Mooney leads Deloitte’s U.S. life sciences consulting practice. A strategy
and operations practitioner with over twenty two years of consulting
experience, he has assisted senior executives from many cultures address the
difficult, complex business issues associated with value creation through
growth, asset effectiveness and cost containment.
A long time European resident who has recently moved to the US, most of Mr
Mooney’s experience has been international. He has conducted major
consulting engagements in North and South America, Europe and Asia for
pharmaceuticals companies, biotechs, medical device manufacturers, and
specialty and commodity chemicals manufacturers. His clients include
companies such as Roche, Novartis, Amgen, Applied Bio, Stryker, Bayer,
Johnson & Johnson, Pfizer, Akzo Nobel, Sanofi-Aventis, GlaxoSmithKline, DSM,
Broken Hill Proprietary and the Government of Argentina.
Mr Mooney has held a number of leadership roles within the firm. He has
served as the Chief Executive Officer of Deloitte Consulting Nederland B.V., as
the firm’s Industry Practice Director, Europe Manufacturing and as a member
of the firm’s European Management Committee.
Beginning his professional career with USX Corporation prior to joining Touche
Ross & Co., Mr Mooney then worked for Braxton Associates, a global strategy
consulting firm, for eight years before rejoining the merged Deloitte & Touche.
He has a B.A. in History and Economics from Washington & Jefferson College
and an M.B.A. from the Katz School, University of Pittsburgh.
Dr Simon Moroney
Chief Executive Officer
MorphoSys AG
Dr Simon Moroney is one of MorphoSys’s co-founders. He studied chemistry
in his native New Zealand, and was a Commonwealth Scholar to the University
of Oxford, where he completed a D. Phil. in Chemistry in 1984. Prior to cofounding
MorphoSys in 1992, Dr Moroney held positions at the University of
Cambridge, UK, at the University of British Columbia, Canada, and in the
Chemistry Department of the ETH in Zurich, Switzerland. Subsequently he
was an Associate in the Harvard Medical School, Boston, U.S.A., and an
employee of ImmunoGen Inc, where he worked on the development of
antibody-based cancer drugs. In 2002, Dr Moroney was awarded the
Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal
Republic of Germany) for his services to the biotechnology industry.
–– 10 ––
Mr Rajiv Narang
Founder and Chief Executive Officer
Erehwon Innovation Consulting Pvt Ltd
Mr Narang’s passion and mission is to fuel the growth of innovative leaders
and organisations. He has, over the last 17 years, developed a keen insight into
‘what does it take for leaders and organisations to innovate and grow’. He has
accomplished this through leading ‘Innovation for growth’ assignments with a
number of organisations across different sectors. Some of his key clients
include Novartis, Nokia, Development bank of Singapore, Bank of America,
ESPN, International Flavours and Fragrances, Max New York Life, Unilever,
Motorola, Bharti – Airtel and Marico Industries.
He has also directly engaged in researching ‘Innovative leaders and
organisations’ especially in Asia to develop fresh path-breaking ideas and
insights and has been invited to speak at a number of national and
international conferences. Some of these are The Strategic Innovators’ Forum
at Barcelona, Delivering Effective Innovation at London, Unlocking Innovation –
Convergence 2005 and 2006, The CII Innovation Summit, HRD Asia Congress
in Singapore, The Economist Annual CEO’s Conclave, AIMA annual convention,
FMCGs Conclave and CII’s India Governing Council. As a result of his
experience in not only in business but social innovation, he has also been
invited to consult with and guide large national and state level change and
innovation projects.
He is the innovation consultant to the ‘Innovation for India’ foundation and also
a member of the managing council.
Mr Gary Noon
Chief Executive Officer
Aegate
Gary Noon has 25 years’ experience in the pharmaceutical industry, fulfiling a
number of roles including senior positions in general management, marketing,
business development and sales in the US and Europe. He has worked for
many of the world’s leading pharmaceutical companies such as Roche, Bristol
Myers Squibb, Glaxo Wellcome and Warner Lambert and was President of IMS
Health in the US. He has particular expertise in strategic marketing, supply
chain management and product development and commercialisation. Before
joining Aegate, Mr Noon was Senior Vice President and Head of
Pharmaceuticals at Diversa Corporation.